{
    "organizations": [],
    "uuid": "081d980fa7664d6895f864a50d29f957f8ff2bd4",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-irom-group-unit-id-pharma-signs-ip/brief-irom-group-unit-id-pharma-signs-ips-cell-generation-technology-licensing-agreement-with-u-s-based-quralis-idUSL4N1PS1ZG",
    "ord_in_thread": 0,
    "title": "BRIEF- I'rom Group unit ID Pharma signs iPS cell generation technology licensing agreement with U.S.-based QurAlis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 2(Reuters) - Iâ€˜rom Group Co Ltd\n* Says its wholly owned unit ID Pharma concluded an iPS cell generation technology licensing agreement with U.S.-based QurAlis Corporation\nSource text in Japanese: goo.gl/a2Qms7\nFurther company coverage: (Beijing Headline News)\n ",
    "published": "2018-02-02T12:18:00.000+02:00",
    "crawled": "2018-02-02T13:01:09.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "rom",
        "group",
        "co",
        "ltd",
        "say",
        "wholly",
        "owned",
        "unit",
        "id",
        "pharma",
        "concluded",
        "ip",
        "cell",
        "generation",
        "technology",
        "licensing",
        "agreement",
        "quralis",
        "corporation",
        "source",
        "text",
        "japanese",
        "company",
        "coverage",
        "beijing",
        "headline",
        "news"
    ]
}